Molecular Biology Small Molecule Targeted Protein Degradation 
Drug Discovery World
OCTOBER 16, 2023
Professor Henrik Daub , Founder and CSO, NEOsphere Biotechnologies looks at the advancements taking place in proteomics and how targeted protein degradation represents a promising approach for developing new treatments for life-threatening diseases.
The Pharma Data
SEPTEMBER 15, 2020
Our Trilomer® platform of peptidomimetic binders allows for the targeted inhibition of disease-causing proteins, for the treatment of cancer, autoimmune diseases, infectious diseases, and others. Each site has a complete molecular biology core facility that allows companies to do experiments on day one, not year one.
Expert insights. Personalized for you.
147 
Let's personalize your content